


CHIR-99021 [252917-06-9]

#Cat: NB-64-12358-2mg	Size: 2 mg
#Cat: NB-64-12358-5mg	Size: 5 mg
#Cat: NB-64-12358-10mg	Size: 10mg
#Cat: NB-64-12358-25mg	Size: 25mg
#Cat: NB-64-12358-50mg	Size: 50mg
#Cat: NB-64-12358-100mg	Size: 100mg
#Cat: NB-64-12358-200mg	Size: 200mg
#Cat: NB-64-12358-500mg	Size: 500mg
#Cat: NB-64-12358-1mL	Size: 1mL

Chemical Properties

CAS No. :	252917-06-9
Formula:	C ₂₂ H ₁₈ Cl ₂ N ₈
Molecular Weight :	465.34
Appearance:	Solid
Storage:	store at low temperature Powder: -20°C for 3 years In solvent: -80°C for 1 year



Biological Description

Description	CHIR-99021 (CT99021) is an activator of the Wnt/β-catenin signaling pathway and a GSK-3α/β inhibitor (IC ₅₀ =10/6.7 nM) with selective and oral activity. CHIR-99021 induces cellular autophagy, which enhances self-renewal in mouse and human embryonic stem cells.
Targets (IC ₅₀)	Autophagy, GSK-3, Wnt/beta-catenin
In vitro	<p>METHODS: Mouse stem cells ES-D3 were treated with CHIR-99021 (1-10 μM) for 72h. Cell growth inhibition was detected using MTT.</p> <p>RESULTS: CHIR-99021 dose-dependently inhibited ES-D3 cell growth with an IC₅₀ of 4.9 μM. [1]</p> <p>METHODS: Mouse embryonic stem cells J1 mESCs and mouse embryoma cells F9 mEC were treated with CHIR-99021 (3 μM) for 24h. The expression levels of target proteins were detected by immunofluorescence.</p> <p>RESULTS: After CHIR-99021 treatment, β-linker proteins were increased in the cytoplasm and nucleus of J1-mESCs and F9-mEC cells. [2]</p> <p>METHODS: Human Tenon fibroblast HTFs were treated with CHIR-99021 (5 μM) for 48h, and the expression levels of target proteins were detected by Western Blot.</p> <p>RESULTS: The production of the active form of GSK-3β (p-GSK-3β (Y216)) was significantly reduced by CHIR-99021 treatment. [3]</p>
In vivo	<p>METHODS: To test the antitumor activity in vivo, CHIR-99021 (37.5 mg/kg/twice daily on days 0-3, 6-10, 13-17, and 20) was orally administered and paclitaxel (10 mg/kg/one dose on day 0) was intraperitoneally injected into Balb/c nude mice harboring human non-small cell lung cancer tumor H1975.</p> <p>RESULTS: CHIR-99021 and paclitaxel synergistically inhibited NSCLC tumor growth in vivo. [4]</p>

	<p>METHODS: To investigate whether direct pharmacological inhibition of GSK-3 alters the positive potentiation of alcohol in mice, CHIR-99021 (1-10 mg/kg) was administered by single intraperitoneal injection to C57BL/6J mice with a history of alcohol or sucrose self-administration.</p> <p>RESULTS: CHIR-99021 dose-dependently increased alcohol-enhanced responses with no effect on sucrose self-administration or locomotor activity. CHIR-99021 significantly decreased pGSK-3β expression in all brain regions tested, decreased PICK1 and increased total GluA2 expression only in NAcB. [5]</p>
Kinase Assay	<p>Kinases were purified from SF9 cells through the use of their His or Glu tag. Glu-tagged proteins were purified as described, and His-tagged proteins were purified according to the manufacturer's instructions. Kinase assays were performed in 96-well plates with appropriate peptide substrates in a 300-μl reaction buffer (variations on 50 mM Tris-HCl, pH 7.5, 10 mM MgCl₂, 1 mM EGTA, 1 mM dithiothreitol, 25 mM β-glycerophosphate, 1 mM NaF, and 0.01% bovine serum albumin). Peptides had Km values from 1 to 100 μM. CHIR 99021 or CHIR GSKIA was added in 3.5 μl of Me₂SO, followed by ATP to a final concentration of 1 μM. After incubation, triplicate 100-μl aliquots were transferred to Combiplate 8 plates containing 100 μl/well of 50 μM ATP and 20 mM EDTA. After 1 hour, the wells were rinsed five times with phosphate-buffered saline, filled with 200 μl of scintillation fluid, sealed, and counted in a scintillation counter 30 min later. All of the steps were at room temperature. The percentage of inhibition was calculated as $100 \times (\text{inhibitor} / \text{no enzyme control}) / (\text{Me}_2\text{SO control} / \text{no enzyme control})$ [4].</p>
Cell Research	<p>The Wnt/beta-catenin reporter assay was performed with the M50 Super 8\times TOPFlash and M51 Super 8\times FOPFlash vector containing the firefly luciferase gene under the control of TCF/LEF binding sites or mutated bindings sites. 12,500 cells were seeded overnight on gelatine-coated 96-well plates in LIF-containing ES cell medium. On the next day, the cells were transfected using Lipofectamine with one of the aforementioned vectors plus pGL4.75 [hRluc/CMV] encoding the renilla luciferase reporter gene hRluc as a transfection control. Six hours after transfection the medium was changed to medium devoid of LIF, with reduced serum, and supplemented with 5μM CHIR-99021. The Dual-Luciferase reporter assay system was employed 48 and 72h after the medium change to follow the luminescence reaction using a GloMax-multi detection system [4].</p>
Animal Research	<p>Blood was obtained by shallow tail snipping at lidocaine-anesthetized tips. Blood glucose was measured directly or heparinized plasma was collected for measurement of glucose or insulin. Animals were prebled and randomized to vehicle control or GSK-3 inhibitor treatment groups. For glucose tolerance tests (GTTs), animals fasted throughout the procedure with food removal early in the morning, 3 h before the first prebleed (db/db mice), or the previous night, 16 h before the bleed (ZDF rats). When the time course of plasma glucose and insulin changes in fasting ZDF rats was measured, food was removed ~16 h before test agent administration. The glucose challenges in</p>

	the GTT were 1.35 g/kg i.p. (ipGTT) or 2 g/kg via oral gavage (oGTT). CHIR-99021 were formulated as solutions in 20 mmol/l citrate-buffered 15% Captisol or as fine suspensions in 0.5% carboxymethylcellulose [1].
--	---

Solubility Information

Solubility	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 0.93 mg/mL (2 mM), Solution. DMSO: 105 mg/mL (225.64 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1mM	2.149 mL	10.7448 mL	21.4897 mL
5mM	0.4298 mL	2.149 mL	4.2979 mL
10mM	0.2149 mL	1.0745 mL	2.149 mL
50mM	0.043 mL	0.2149 mL	0.4298 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

- Naujok O, et al. Cytotoxicity and activation of the Wnt/beta-catenin pathway in mouse embryonic stem cells treated with four GSK3 inhibitors. *BMC Res Notes*. 2014 Apr 29;7:273.
- Lin Y Y, Yao R, Zhuang J, et al. PACT inhibits the replication of SARS-CoV-2 through the blockage of GSK-3 β -N-nsp3 cascade. *Journal of Medical Virology*. 2023; 95(6): e88232.
- Wang W, Ren S, Lu Y, et al. Inhibition of Syk promotes chemical reprogramming of fibroblasts via metabolic rewiring and H₂S production. *The EMBO Journal*. 2021 Jun 1;40(11):e106771. doi: 10.15252/embj.2020106771. Epub 2021 Apr 28.
- Yuan Y, Chen H, Ou S, et al. Generation of mitochondria-rich kidney organoids from expandable intermediate mesoderm progenitors reprogrammed from human urine cells under defined medium. *Cell & Bioscience*. 2022, 12(1):1-20.
- Lin R, Zhai Z, Kuang J, et al. H3K27ac mediated SS18/BAFs relocation regulates JUN induced pluripotent-somatic transition. *Cell & Bioscience*. 2022, 12(1):1-14.
- Wu M, Zhang X, Zhang W, et al. Cancer Stem Cell Regulated Phenotypic Plasticity Protects Metastasized Cancer Cells from Ferroptosis. *Nature Communications*. 2022, 13(1):1-16.
- Mendonça L S, Henriques D, Fernandes V, et al. Graft-derived neurons and bystander effects are maintained for six months after human iPSC-derived NESc transplantation in mice's cerebellar. *Scientific Reports*. 2024, 14(1):3236.
- Wang Z, Li F, Feng C, et al. 1-Naphthaleneacetic Acid Improved In Vitro Cell Culturing by Inhibiting Apoptosis. *Advanced Biology*. 2024, 2300953.
- Wan C, Huang Y, Xue X, et al. HELQ deficiency impairs the initiation of primordial germ cell-like cells. *FEBS Open Bio*. 2024.
- Yuan F, Zhang R, Li J, et al. CCR5-overexpressing mesenchymal stem cells protect against experimental autoimmune uveitis: insights from single-cell transcriptomic analysis. *Journal of Neuroinflammation*. 2024, 21(1): 136.
- Zhang R, Chen Y, Feng Z, et al. Reprogramming Human Urine Cells into Intestinal Organoids with Long-Term Expansion Ability and Barrier Function. *Heliyon*. 2024.
- Ma Z, Huang X, Kuang J, et al. Cpt1a Drives primed-to-naïve pluripotency transition through lipid remodeling. *Communications Biology*. 2024, 7(1):1223.
- Yu Y, Li X, Jiao R, et al. H3K27me₃-H3K4me₁ transition at bivalent promoters instructs lineage specification

in human blastocysts. *Cell Bioscience*. 2023, 13(1):1-20.

Wu Y, et al. GSK3 inhibitors CHIR99021 and 6-bromoindirubin-3'-oxime inhibit microRNA maturation in mouse embryonic stem cells. *Sci Rep*. 2015 Mar 27;5:8666.

Xue J, Chu Y, Huang Y, et al. A tumorigenicity evaluation platform for cell therapies based on brain organoids. *Translational Neurodegeneration*. 2024, 13(1):53.

Feng Y, Lu B, Huang Y, et al. Perfluorooctanoic Acid Induces Ferroptosis in Hepatocytes via Oxidative Stress and AKT/GSK3 β / β -Catenin Pathway Disruption. *ACS Omega*. 2025

Sex-biased gene expression during neural differentiation of human embryonic stem cells

Lee SY, et al. The Effect of CHIR 99021, a Glycogen Synthase Kinase-3 β Inhibitor, on Transforming Growth Factor β -Induced Tenon Fibrosis. *Invest Ophthalmol Vis Sci*. 2021 Dec 1;62(15):25.

Wu M, Zhang X, Zhang W, et al. Paracrine secretion of IL8 by breast cancer stem cells promotes therapeutic resistance and metastasis of the bulk tumor cells. *Cell Communication and Signaling*. 2023, 21(1): 1-17.

Han L, Song B, Zhang P, et al. PC3T: a signature-driven predictor of chemical compounds for cellular transition. *Communications Biology*. 2023, 6(1): 989.

O'Flaherty L, et al. Tumor growth suppression using a combination of taxol-based therapy and GSK3 inhibition in non-small cell lung cancer. *PLoS One*. 2019 Apr 10;14(4):e0214610.

Faccidomo S, et al. Pharmacological inhibition of glycogen synthase kinase 3 increases operant alcohol self-administration in a manner associated with altered pGSK-3 β , protein interacting with C kinase and GluA2 protein expression in the reward pathway of male C57BL/6J mice. *Behav Pharmacol*. 2020 Feb;31(1):15-26.

Yang Y, Xiao L, Xue Y, et al. ZBTB7A regulates primed-to-naïve transition of pluripotent stem cells via recognition of the PNT-associated sequence by Zinc Fingers 1–2 and recognition of γ -globin – 200 gene element by Zinc Fingers 1–4. *The FEBS Journal*. 2023

Gong-Bo Fu, Wei-Jian Huang, Min Zeng, Xu Zhou, Hong-Ping Wu, Chang-Cheng Liu, Han Wu, Jun Weng, Hong-Dan Zhang, Yong-Chao Cai, Charles Ashton, Min Ding, Dan Tang, Bao-Hua Zhang, Yi Gao, Wei-Feng Yu, Bo Zhai, Zhi-Ying He, Hong-Yang Wang, and He-Xin Yan. Expansion and differentiation of human hepatocyte-derived liver progenitor-like cells and their use for the study of hepatotropic pathogens [J]. *Cell Research*. 2019 Jan;29(1):8-22.

Yang Z, Liu H, Song R, et al. Reduced MAGI3 level by HPV18E6 contributes to Wnt/ β -catenin signaling activation and cervical cancer progression. *FEBS Open bio*. 2021, 11(11): 3051.

He W, Zhu X, Xin A, et al. Long-term maintenance of human endometrial epithelial stem cells and their therapeutic effects on intrauterine adhesion. *Cell & Bioscience*. 2022, 12(1): 1-20.

Fu G B, Huang W J, Zeng M, et al. Expansion and differentiation of human hepatocyte-derived liver progenitor-like cells and their use for the study of hepatotropic pathogens. *Cell Research*. 2019, 29(1): 8-22

Ma X, Lu Y, Zhou Z, Human expandable pancreatic progenitor-derived β cells ameliorate diabetes. *Science Advances*. 2022, 8(8): eabk1826.